Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2483799 | 0.90 | DRD2 (0.61) | DRD2KCNA3CTSKJAK2JAK1 | |
| SCHEMBL27225010 | 0.90 | DRD2 (0.58) | DRD2KCNA3CTSKJAK2JAK1 | |
| SCHEMBL1604214 | 0.86 | DRD2 (0.55) | DRD2KCNA3CTSKBTKCA1 | |
| SCHEMBL8187882 | 0.86 | DRD2 (0.55) | DRD2KCNA3CTSKBTKCA1 | |
| SCHEMBL30399978 | 0.83 | DRD2 (0.55) | DRD2JAK2JAK1 | |
| SCHEMBL3489007 | 0.83 | DRD2 (0.55) | DRD2KCNA3CTSKJAK2JAK1 | |
| SCHEMBL12501447 | 0.82 | DRD2 (0.62) | DRD2KCNA3CTSKJAK2JAK1 | |
| SCHEMBL14651348 | 0.82 | DRD2 (0.62) | DRD2KCNA3CTSKJAK2JAK1 | |
| SCHEMBL14760990 | 0.82 | DRD2 (0.51) | DRD2KCNA3CTSKJAK2JAK1 | |
| SCHEMBL6584897 | 0.82 | DRD2 (0.51) | DRD2KCNA3CTSKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230104076-A1 | PLK1 Selective Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-04-06 | — | — | US | disclosed |
| CN-1653063-A | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofurylcarbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, and method for producing the same, pharmaceutical composition containing the same and i | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| EP-1076055-B1 | 1- (1-SUBSTITUTED-4-PIPERIDINYL)METHYL]-4-PIPERIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THESE COMPOUNDS | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-11-24 | — | — | EP | disclosed |
| EP-1362857-B1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | DAINIPPON PHARMACEUTICAL CO (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-6696468-B2 | GASTROINTESTINAL MOTILITY ENHANCER OR PROKINETIC AGENT; AFFINITY FOR 5-HT4 RECEPTOR; REDUCED SIDE EFFECTS TO HEART OR CENTRAL NERVOUS SYSTEM | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| WO-2003097638-A1 | (S)-4-AMINO-5-CHLORO-2-METHOXY-N-[1-[1-(2-TETRAHYDROFURYLCARBONYL)-4-PIPERIDINYLMETHYL]-4-PIPERIDINYL]BENZAMIDE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-27 | — | — | WO | disclosed |
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1362857-A1 | (S)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinymethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-6294555-B1 | SEROTONIN HT3 RECEPTOR ANTAGONIST FOR GASTROINTESTINAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-09-25 | — | — | US | disclosed |
| EP-1076055-A1 | 1- (1-SUBSTITUTED-4-PIPERIDINYL)METHYL]-4-PIPERIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THESE COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 2001-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | DRD2 3885/4885KCNA3 3663/4885CTSK 1058/4885 |
| US-20230104076-A1 | PLK1 Selective Degradation Inducing Compound | PLK1, BUB1B, BUB1 | DRD2 3885/4885KCNA3 3663/4885CTSK 1058/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | DRD2 3885/4885KCNA3 3663/4885CTSK 1058/4885 |
| US-20030216433-A1 | (S)-4-amino-5-chloro-2-methoxy-N-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | GIPR, MLNR, HTR5A | DRD2 12/4885KCNA3 889/4885CTSK 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.